Intelence and Emtriva drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Intelence and Emtriva. Common interactions include dysstasia among females and anxiety among males.

The phase IV clinical study analyzes what interactions people who take Intelence and Emtriva have. It is created by eHealthMe based on reports of 94 people who take Intelence and Emtriva from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

94 people who take Intelence and Emtriva together, and have interactions are studied.


What is Intelence?

Intelence has active ingredients of etravirine. It is often used in hiv infection. eHealthMe is studying from 3,453 Intelence users for its effectiveness, alternative drugs and more.

What is Emtriva?

Emtriva has active ingredients of emtricitabine. eHealthMe is studying from 2,015 Emtriva users for its effectiveness, alternative drugs and more.

Number of Intelence and Emtriva reports submitted per year:

Intelence and Emtriva drug interactions.

Common Intelence and Emtriva drug interactions by gender *:

female:

  1. Dysstasia
  2. Enlarged clitoris
  3. Fatigue
  4. Feeling hot
  5. Foetal exposure during pregnancy
  6. Gait disturbance
  7. Glomerular filtration rate decreased
  8. Glomerulosclerosis
  9. Hepatocellular injury
  10. Hyperandrogenism

male:

  1. Anxiety
  2. Pain
  3. Lymphoedema
  4. Multiple-drug resistance
  5. Pancytopenia
  6. Pyrexia
  7. Skin lesion
  8. Neoplasm progression
  9. Bone density decreased
  10. Renal failure

Common Intelence and Emtriva drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Anhedonia
  2. Anxiety
  3. Emotional distress
  4. Fatigue
  5. Impaired work ability
  6. Mobility decreased
  7. Myocardial infarction
  8. Osteopenia
  9. Pain
  10. Quality of life decreased

40-49:

  1. Anhedonia
  2. Anxiety
  3. Chronic kidney disease
  4. Emotional distress
  5. Pain
  6. Bone density decreased
  7. Renal impairment
  8. Hip arthroplasty
  9. Renal failure
  10. Bone loss

50-59:

  1. Intestinal haematoma
  2. Joint destruction
  3. Multiple fractures
  4. Nephrogenic anaemia
  5. Nephrolithiasis
  6. Osteoarthritis
  7. Osteonecrosis
  8. Pelvic fracture
  9. Renal arteriosclerosis
  10. Renal transplant

60+:

  1. Lower gastrointestinal haemorrhage
  2. Shock haemorrhagic
  3. Nerve injury
  4. Spinal cord compression
  5. Urinary incontinence
  6. Anhedonia
  7. Anxiety
  8. Decreased activity
  9. Decreased interest
  10. Depressed mood

Common conditions people have *:

  1. Hiv Infection: 78 people, 82.98%
  2. Kaposi's Sarcoma (a tumour caused by human herpes virus): 18 people, 19.15%

* Approximation only. Some reports may have incomplete information.

Do you take Intelence and Emtriva?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Intelence and Emtriva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Intelence interactions:

Browse all interactions between Intelence and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Emtriva interactions:

Browse all interactions between Emtriva and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on etravirine and emtricitabine (the active ingredients of Intelence and Emtriva, respectively), and Intelence and Emtriva (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Intelence and Emtriva.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: